Résumé
The aim of this study was to explore the neuroprotective effect and mechanism of XingNaoJing injections (XNJ) on cerebral ischemia injury and blood-brain barrier (BBB) disruption. Middle cerebral artery occlusion (MCAO) method was applicated to establish the model of cerebral ischemia/reperfusion (I/R) injury in rats. BBB permeability after I/R injury was assessed with the leaking amount of Evans Blue and the expression of occludin and ZO-1. The expression of NOD-like receptor family, pyrin domain containing (NLRP3) was checked to explore the inhibition of inflammation by XNJ. The results showed that XNJ could significantly increase the survival percent, decrease the infarct area and ameliorate neurological deficits and brain damage after I/R injury. Leaking amount of Evans Blue was reduced by XNJ, and the expression of tight junction protein, occludin and ZO-1 was also up-regulated by XNJ, which showed a role of protection on BBB disruption. The expression of NLRP3 was inhibited after exposure of XNJ, which was associated with inhibition of the inflammatory response. In summary, XNJ could suppress NLRP3 inflammasomes and improve BBB disruption and brain damage in rats after cerebral I/R injury, which provided a beneficial insight to further explore XNJ.
Résumé
Objective To investigate the application of xingnaojing injections ( XNJI) in inpatients and further provide a reference for the rational drug use. Methods The retrospective investigation was carried out by reviewing 186 hospitalization records with XNJI from a certain hospital from January 2014 to June 2015. The usage, dosage, and indication of XNJI were analyzed. Results Unlabeled use of XNJI was found in the neurology department inpatients. 59. 7% inpatients were treated with overdosed XNJI, and 13. 4% were treated with a single drug dose of 40 mL. The inappropriate solvent selection accounted for 49. 5%. Compatibility of XNJI and western medicine injection accounted for 54. 8%. It was also found that XNJI was used together with potassium chloride in clinic (47. 8%). Conclusion There exist some irrational uses of XNJI in clinic, thus the use and management of traditional Chinese medicine injections should be standarized.
Résumé
Objective:To observe the effect of Xingnaojing injections combined with edaravone in the treatment of acute cerebral hemorrhage. Methods:The patients with acute cerebral hemorrhage were randomly divided into the observation group and the control group with 44 cases in each. The two groups were both given conventional treatment. The control group was treated with 30mg edara-vone injections in 0. 9% 500ml sodium chloride infusions, ivd (infused in 30min), bid, while the observation group was additionally given 10ml Xingnaojing injections in 5. 0% 250ml glucose infusions, ivd, qd. After the 4-week treatment, NIHSS score, GCS score, brain edema and hematoma volume, the levels of high sensitive C reactive protein (hs-CRP) and interleukin-6 (IL-6) before and after the treatment in the two groups were observed and compared, and adverse drug reactions were also recorded. Results: After the treat-ment, GCS score was significantly improved (P0. 05). The levels of hs-CRP and IL-6 were decreased significantly after the treatment in the two groups (P0. 05). Conclusion: Compared with edaravone alone, Xingnaojing injections combined with edaravone in the treatment of acute cerebral hemorrhage show more significant efficacy.